Addex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K is a report of a foreign private issuer filed by Addex Therapeutics Ltd. for the month of June 2025. The filing, dated June 6, 2025, serves to incorporate by reference a press release issued on the same date (Exhibit 99.1). The registrant is headquartered in Geneva, Switzerland, and files annual reports under Form 20-F.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document acts as a conduit for a press release and does not contain standalone financial statements or quantitative performance data.
Material Changes
The filing text does not provide a clear value regarding material changes versus the prior comparable period. The specific nature of the update contained in the referenced press release is not detailed within the Form 6-K body.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. These details are contained within the attached press release (Exhibit 99.1) which is incorporated by reference but not reproduced in the provided text.
Key Facts for Investor Verification
- Verify the content of the press release dated June 6, 2025 (Exhibit 99.1), as the Form 6-K contains no substantive operational or financial details.
- Confirm the impact of the press release announcement on the company's registration statements on Form F-3 and Form S-8.
- Note that the filing was signed by Tim Dyer, Chief Executive Officer, on June 6, 2025.